Novartis AG ADR (NVS)vsEnvista Holdings Corp (NVST)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
NVST
Envista Holdings Corp
$25.90
-2.23%
HEALTHCARE · Cap: $4.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1980% more annual revenue ($56.58B vs $2.72B). NVS leads profitability with a 23.9% profit margin vs 1.7%. NVS trades at a lower P/E of 21.2x. NVST earns a higher WallStSmart Score of 56/100 (C).
NVS
Buy51
out of 100
Grade: C-
NVST
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+57.7%
Fair Value
$71.58
Current Price
$25.90
$45.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Earnings expanding 3146.0% YoY
15.0% revenue growth
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
ROE of 1.6% — below average capital efficiency
1.7% margin — thin
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : NVST
The strongest argument for NVST centers on Price/Book, EPS Growth, Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : NVST
The primary concerns for NVST are Return on Equity, Profit Margin, P/E Ratio. A P/E of 92.5x leaves little room for execution misses. Thin 1.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while NVST is a value play — different risk/reward profiles.
NVST carries more volatility with a beta of 0.98 — expect wider price swings.
NVST is growing revenue faster at 15.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVST scores higher overall (56/100 vs 51/100) and 15.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Envista Holdings Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?